In the Indian pharmaceutical industry, there were 25 M&A deals announced in Q3 2023, worth a total value of $1.5bn, according to GlobalData’s Deals Database. The $679.9m majority acquisition of Glenmark Life Sciences by Nirma was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in India increased by 443% in Q3 2023 compared with the previous quarter’s total of $276.3m and rose by 190% as compared to Q3 2022. Related deal volume increased by 47% in Q3 2023 versus the previous quarter and was 56% higher than in Q3 2022.
The top-ranked legal advisorss supporting these M&A deals in India Q3 2023 were Khaitan & Co; AZB & Partners; DSK Legal with 3, 2, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.